Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.
View Top Employees from Domain TherapeuticsWebsite | https://www.domaintherapeutics.com |
Revenue | $5 million |
Funding | $13.7 million |
Employees | 107 (107 on RocketReach) |
Founded | 2008 |
Phone | +33 3 90 40 61 50 |
Technologies |
JavaScript,
HTML,
PHP
+14 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Business Services General, Pharmaceuticals, Business Services, Biotechnology |
Web Rank | 6 Million |
Keywords | Domain Therapeutics, Domain Therapeutic, Youssef Bennani Dropshipping |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular Domain Therapeutics employee's phone or email?
The Domain Therapeutics annual revenue was $5 million in 2024.
Pascal Neuville is the CEO of Domain Therapeutics.
107 people are employed at Domain Therapeutics.
The NAICS codes for Domain Therapeutics are [5417, 541, 54, 541714, 54171].
The SIC codes for Domain Therapeutics are [87, 873].